Abstract
INTRODUCTION
OBJECTIVES AND GOALS OF STUDY
The aim of this report is to provide a range of information-from detailed
market analyses through industry trends-to quantify and qualify the market for
fixed-dose combination drugs for the treatment of selected major diseases.
Forecasts and trends are gleaned from industry sources as well as from
considered assessment of available and emerging technologies. The report
develops forecasts for selected disease categories of the fixed-dose
combination drug market from 2005 through 2012 and examines strategies
employed by biotechnology companies and pharmaceutical firms to develop and
market products in this market sector.
CONTRIBUTION OF THE STUDY AND FOR WHOM
Fixed-dose combination drugs have been used for some time in certain
therapeutic categories such as antihypertensives, although they were often
reserved for second- or third-line therapy. With the revolution in the
survival rates of patients suffering from human immunodeficiency virus (HIV)
infection that occurred with the implementation of fixed-drug combination
products for this, this delivery technology received a boost of confidence as
well as an influx of creative applications to other diseases. For the past
several years, a number of fixed-dose combination drugs have been introduced
for a variety of diseases, some for the first time in a particular disease
category. This report discusses the impact of fixed-dose combination drug
technology on these various therapeutic categories, as well as providing
assessments and projections of this technology overall.
The information and analysis presented in this report on fixed-dose
combination products are important assets in decision-making for managers
involved in business development, marketing, market research, product
development, mergers and acquisitions, licensing, business management,
investment banking and deal creation, and to consultants to the pharmaceutical
and biotechnology industry. The study provides a comprehensive analysis of
the current markets for fixed-dose combination products and the market
potential of promising drugs under development.
STUDY SCOPE AND FORMAT
This report analyzes products and applications of fixed-dose combination drugs
utilized in the treatment of cardiovascular diseases (hypercholesterolemia and
hypertension), diabetes, infectious diseases (bacterial infections,
Helicobacter pylori, acquired immune deficiency syndrome-AIDS, HIV infection
and tuberculosis), psychiatric disorders (depression and Alzheimer' s disease)
and respiratory diseases (asthma and chronic obstructive pulmonary
disease-COPD).
Not included in this report are combination products used as oral
contraceptives, combinations of a drug (such as a monoclonal antibody) and a
radioactive component, or combination vaccine products. Also not included are
over-the-counter (OTC) and prescription nonsystemic fixed-dose combination
products.
The scope of the study is worldwide. The Overview section provides a
discussion of the history and advantages of fixed-dose combination drug
products. Also described are the leading diseases for which fixed-dose
combination products are available or are projected to be introduced during
the forecast period. This section also discusses the various types of
products available or in development within the categories included in this
report.
The Products and Applications section provides synopses of more than 70
fixed-dose combination drug products, including those currently marketed and
those in Phase II or later development. Comparative product and sales
analyses are provided for individual products. Tables include current and
forecasted sales by individual product, when possible, as well as worldwide
market size and growth estimates for fixed-dose combination drug categories as
a whole.
The section on Industry Structure provides an overview of strategies employed
by Big Pharma in this decade of a high number of top-selling drug patent
expirations, how this phenomenon relates to the overall pharmaceutical
industry and biotechnology companies and, in particular, the role of
fixed-dose combination drugs in the increasingly competitive pharmaceutical
industry.
The section on Company Profiles emphasizes companies that lead the
pharmaceutical and biotechnology industry in the research and development of
fixed-dose combination drugs and the innovative products they have launched or
have in development.
View Cart
